Copd
Abstract
Introduction: Chronic obstructive pulmonary disease (COPD) is a disease state characterised by airflow limitation that is not fully reversible. The airflow limitation is usually progressive and associated with an abnormal inflammatory response of the lungs to noxious particles or gases. Classically, it is thought to be a combination of emphysema and chronic bronchitis, although only one of these may be present in some people with COPD. The main risk factor for the development and deterioration of COPD is smoking.
Methods and outcomes: We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of maintenance drug treatment in stable COPD? What are the effects of smoking cessation interventions in people with stable COPD? What are the effects of non-drug interventions in people with stable COPD? We searched: Medline, Embase, The Cochrane Library, and other important databases up to April 2010 (Clinical Evidence reviews are updated periodically; please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).
Results: We found 119 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.
Conclusions: In this systematic review, we present information relating to the effectiveness and safety of the following interventions: alpha(1) antitrypsin, antibiotics (prophylactic), anticholinergics (inhaled), beta(2) agonists (inhaled), corticosteroids (oral and inhaled), general physical activity enhancement, inspiratory muscle training, nutritional supplementation, mucolytics, oxygen treatment (long-term domiciliary treatment), peripheral muscle strength training, psychosocial and pharmacological interventions for smoking cessation, pulmonary rehabilitation, and theophylline.
Similar articles
-
Copd.BMJ Clin Evid. 2008 Dec 15;2008:1502. BMJ Clin Evid. 2008. PMID: 19445783 Free PMC article. Review.
-
Asthma in adults.BMJ Clin Evid. 2011 Jul 13;2011:1512. BMJ Clin Evid. 2011. PMID: 21749735 Free PMC article. Review.
-
Asthma in adults.BMJ Clin Evid. 2010 Jan 21;2010:1501. BMJ Clin Evid. 2010. PMID: 21718577 Free PMC article. Review.
-
Asthma in adults.BMJ Clin Evid. 2007 Aug 15;2007:1501. BMJ Clin Evid. 2007. PMID: 19454105 Review.
-
Bronchiectasis.BMJ Clin Evid. 2011 Aug 16;2011:1507. BMJ Clin Evid. 2011. PMID: 21846412 Free PMC article. Review.
Cited by
-
Efficacy and safety profile of xanthines in COPD: a network meta-analysis.Eur Respir Rev. 2018 May 2;27(148):180010. doi: 10.1183/16000617.0010-2018. Print 2018 Jun 30. Eur Respir Rev. 2018. PMID: 29720510 Free PMC article. Review.
-
Encapsulation of alpha-1 antitrypsin in PLGA nanoparticles: in vitro characterization as an effective aerosol formulation in pulmonary diseases.J Nanobiotechnology. 2012 May 20;10:20. doi: 10.1186/1477-3155-10-20. J Nanobiotechnology. 2012. PMID: 22607686 Free PMC article.
References
-
- The Global Initiative for Chronic Obstructive Lung Disease. Available at: http://www.goldcopd.com (last accessed 28 April 2011).
-
- American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease: ATS statement. Am J Respir Crit Care Med 1995;152(suppl):77–120. - PubMed
-
- Worlh Health Organization. World Health Report 1999. Making a difference. Available at: http://www.who.int/whr/1999/en/index.html (last accessed 28 April 2011).
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous